In this issue:
Long-term pioglitazone for NASHand prediabetes/type 2 diabetes
Liraglutide added to insulin intype 1 diabetes
Long-term CSII outcomes
Novel glucose-sensing technologyin type 1 diabetes
Micro/macrovascular disease and peripheral arterial disease risk in type 2 diabetes
Hyperglycaemia and adverse perinatal outcomes
Glycaemic control and TB risk
CV safety of glucose-lowering agents added to metformin in type 2 diabetes
CV safety of empagliflozin in type 2 diabetes
Perceptions and experiences of oral medications for type 2 diabetes
Please login below to download this issue (PDF)